CTRI/2015/12/006463已完成未知
A prospective open label multi-centre study to evaluate the safety and efficacy of a topical anti-acne formulation in patients with facial acne.
A Menarini India Private Limited0 个研究点目标入组 36 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 36
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1 Male and female patients aged 18 to 50 years, with a diagnosis of moderate facial acne vulgaris
- •2 Facial inflammatory lesion count > 20 and < 50 both inclusive
- •3 Non inflammatory lesion count of atleast 20-100.
- •4 Investigators Global Assessment Score of 3.
排除标准
- •1 Patients with 2 nodulocystic lesions, prior topical acne treatment or systemic anti inflammatory agents in past 14 days.
- •2 Patients on systemic corticosteroids, antibacterial, immunosuppressant drugs or abrading facial procedures in the past 30 days.
- •3 Patients with other concurrent facial skin disease and patients who are photosensitive or who are likely to engage in activities that involve excessive or prolonged exposure to sunlight.
- •4 Patients with drug induced acne.
- •5 Patients with menopausal disorders.
- •6 Has a history of significant reactions to topical acne treatments, or a known allergy or hypersensitivity to any listed ingredients.
- •7 Use of oral retinoids within 6 months of Baseline visit.
研究者
相似试验
尚未招募
4 期
Comparison of personalised coaching program with standard of care in Type 2 diabetes managementCTRI/2024/05/068043Ragus Healthcare Private Limited
招募中
不适用
Clinical Evaluation of Low Cost Single use Safety syringeCTRI/2017/06/008864Indian Council of Medical Research ICMR
已完成
3 期
Evaluation of DEAT0217 versus standard of care to compare effectiveness and safety in treating moderate psoriasis in adult patientsAdult patients diagnosed with mild to moderate psoriasis.Skin and Connective Tissue DiseasesISRCTN28479470Devintec SAG42
招募中
3 期
A Study to Learn How Gadoquatrane Moves Into, Through, and Out of the Body and How Safe it is in Children (From Birth to <18 Years), Who Will Undergo a Contrast Enhanced MRI (Quanti Pediatric)JPRN-jRCT2011230024Myoishi Masafumi100
进行中（未招募）
不适用
A 7-month research project for children aged from 3 months to 11 years with pulmonary arterial hypertension to find out whether bosentan is best tolerated, and most safe and effective when taken two or three times a dayPulmonary arterial hypertension (PAH) in childrenMedDRA version: 14.0Level: LLTClassification code 10064908Term: Associated with (APAH)System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersMedDRA version: 14.0Level: LLTClassification code 10064909Term: Idiopathic (IPAH)System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersMedDRA version: 14.0Level: LLTClassification code 10064910Term: Familial (FPAH)System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2010-021825-11-CZActelion Pharmaceuticals Ltd.64